RT Journal Article T1 Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis A1 Martinez-Florensa, Mario A1 Consuegra-Fernandez, Marta A1 Aranda, Fernando A1 Armiger-Borras, Noelia A1 Di Scala, Marianna A1 Carrasco, Esther A1 Pachon, Jeronimo A1 Vila, Jordi A1 Gonzalez-Aseguinolaza, Gloria A1 Lozano, Francisco K1 soluble CD6 K1 cecal ligation and puncture K1 polymicrobial peritonitis K1 scavenger receptors K1 sepsis K1 septic shock K1 adjunctive therapy K1 T-cell-activation K1 Pattern-recognition K1 Binding K1 Strategies AB Sepsis still constitutes an unmet clinical need, which could benefit from novel adjunctive strategies to conventional antibiotic therapy. The soluble form of the scavenger-like human CD6 lymphocyte receptor (shCD6) binds to key pathogenic components from Gram-positive and-negative bacteria and shows time-and dose-dependent efficacy in mouse models of monobacterial sepsis. The objective of the present work was to demonstrate the effectiveness of infusing mouse and human sCD6 by different systemic routes, either alone or as adjunctive therapy to gold standard antibiotics, in a lethal model of polymicrobial sepsis. To this end, C57BL/6 mice undergoing high-grade septic shock induced by cecal ligation and puncture (CLP; >= 90% lethality) were infused via the intraperitoneal (i.p.) or intravenous (i.v.) route with shCD6 at different doses and time points, either alone or in combination with imipenem/cilastatin (I/C) at a dose of 33 mg/kg of body weight every 8 h. Significantly reduced mortality and proinflammatory cytokine levels were observed by i.p. infusion of a single shCD6 dose (1.25 mg/kg) 1 h pre-or post-CLP. When using the i.v. route, mice survival was significantly extended by starting shCD6 infusion at later time points post-CLP (up to 6 h after CLP). Significant adjunctive effects on mouse survival were observed by i.p. or i.v. infusion of shCD6 in combination with i.p. I/C post-CLP. Similar results were obtained in mice expressing high sustained levels (5 to 10 mu g/ml) of mouse sCD6 in serum by means of transduction with hepatotropic adeno-associated virus (AAV). Taken together, the data support the conserved antibacterial effects of human and mouse sCD6 and their use as adjunctive therapy in experimental models of complex and severe polymicrobial sepsis. PB Amer soc microbiology SN 0066-4804 YR 2017 FD 2017-01-01 LK http://hdl.handle.net/10668/19001 UL http://hdl.handle.net/10668/19001 LA en DS RISalud RD Apr 13, 2025